Despite encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from pharmacy benefit managers. These insurers are https://keithzdgh376327.blogspothub.com/40726151/company-s-drug-faces-is-dealing-with-pbm-hurdles-a-look-of-reimbursement-disputes